دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Is the parent global assessment a reliable quality of life measure in juvenile idiopathic arthritis?
Giovanni Filocamo, Alessandro Consolaro, Angelo Ravelli
doi : 10.1093/rheumatology/keac600
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2023–2024
How to manage patients perceived as having a mild form of early arthritis?
Diederik De Cock, Sofia Ajeganova, Patrick Verschueren
doi : 10.1093/rheumatology/keac657
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2025–2026
Good common sense and clinical judgment should be the driver for further investigation
Soumya Chatterjee
doi : 10.1093/rheumatology/keac631
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2027–2029
Clinical observation: are nightmares a manifestation of neuropsychiatric lupus?
David P D’Cruz, Melanie Sloan
doi : 10.1093/rheumatology/keac655
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2030–2031
The pre-clinical phase of giant cell arteritis: new clues in the pathogenesis of giant cell arteritis supporting emerging targets
Luca Quartuccio, Elena Treppo, Christian Dejaco
doi : 10.1093/rheumatology/keac697
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2032–2034,
Depression in spondyloarthritis: can we kill two birds with one stone?
Konstantina Magiouf, George E Fragoulis
doi : 10.1093/rheumatology/keac704
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2035–2036
A systematic review of the sex differences in risk factors for knee osteoarthritis
Ingrid A Szilagyi, Jan H Waarsing, Joyce B J van Meurs, Sita M A Bierma-Zeinstra, Dieuwke Schiphof
doi : 10.1093/rheumatology/keac688
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2037–2047
Previous systematic reviews focused on the evidence of common risk factors for knee OA (KOA); however, the effect and strength of association between risk factors and KOA might be different between the two sexes. The aim of the present systematic review was to determine the current evidence on sex differences in the association between risk factors and KOA and their prevalence.
Multibiomarker disease activity score: an objective tool for monitoring rheumatoid arthritis? A systematic review and meta-analysis
Fanni A Meznerics, Lajos V Kemény, Emese Gunther, Eszter Bakó, Fanni Dembrovszky, Bence Szabó, Anna Ascsillán, Elmar Lutz, Dezsö Csupor, Péter Hegyi, András Bánvölgyi, György Nagy
doi : 10.1093/rheumatology/keac715
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2048–2059
The multibiomarker disease activity (MBDA) score is an objective tool for monitoring disease activity in RA. Here we report a systematic review and meta-analysis of the clinical value of the MBDA score in RA.
Improving outcomes in scleroderma: recent progress of cell-based therapies
Dinesh Khanna, Nancy Krieger, Keith M Sullivan
doi : 10.1093/rheumatology/keac628
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2060–2069
Scleroderma is a rare, potentially fatal, clinically heterogeneous, systemic autoimmune connective tissue disorder that is characterized by progressive fibrosis of the skin and visceral organs, vasculopathy and immune dysregulation. The more severe form of the disease, diffuse cutaneous scleroderma (dcSSc), has no cure and limited treatment options.
Thrombocytopaenia in antiphospholipid syndrome: a free radical perspective
Paul R J Ames, Tommaso Bucci, Mira Merashli, Alessia Arcaro, Fabrizio Gentile
doi : 10.1093/rheumatology/keac650
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2070–2075
Thrombosis associated with thrombocytopaenia is an apparent paradox that is present across a wide spectrum of disorders.
Comparison of health-care utilization, costs and health-related quality of life across the subgroups defined by the Keele STarT MSK Tool
Raymond Oppong, Martyn Lewis, Paul Campbell, Kate M Dunn, Nadine E Foster, Jonathan C Hill, Sue Jowett
doi : 10.1093/rheumatology/keac560
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2076–2082
The aim of this study was to describe and compare health economic outcomes [health-care utilization and costs, work outcomes, and health-related quality of life (EQ-5D-5L)] in patients classified into different levels-of-risk subgroups by the Keele STarT MSK Tool.
Early characterization of difficult-to-treat rheumatoid arthritis by suboptimal initial management: a multicentre cohort study
Alessandro Giollo, Margherita Zen, Maddalena Larosa, Davide Astorri, Mariangela Salvato, Antonia Calligaro, Konstantinos Botsios, Cristina Bernardi, Gerolamo Bianchi, Andrea Doria
doi : 10.1093/rheumatology/keac563
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2083–2089
To demonstrate that unsuccessful treatment optimization in early disease is associated with difficult-to-treat RA (D2T-RA).
Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis
Ryan M Hum, Pauline Ho, Nisha Nair, Meghna Jani, Ann W Morgan, John D Isaacs, Anthony G Wilson, Kimme L Hyrich, Darren Plant, Anne Barton, the BRAGGSS Collaborators
doi : 10.1093/rheumatology/keac564
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2090–2097
Interventions aimed at increasing TNF-α inhibitor serum drug levels (SDLs) may improve treatment response; however, previous studies suggesting SDL cut-offs have not accounted for treatment adherence. The aim of this study was to establish the relationship between adalimumab/certolizumab SDLs and EULAR good vs non-/moderate response and to define SDL cut-offs associated with good response in fully adherent patients.
Favourable effect of a ‘second hit’ after 13 weeks in early RA non-responders: the Amsterdam COBRA treat-to-target randomized trial
Linda Hartman, Linda A Rasch, Samina A Turk, Marieke M ter Wee, Pit J S M Kerstens, Conny J van der Laken, Michael T Nurmohamed, Dirkjan van Schaardenburg, Lilian H D van Tuyl, Alexandre E Voskuyl, Maarten Boers, Willem F Lems
doi : 10.1093/rheumatology/keac582
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2098–2105,
The aim of this study was to investigate the effect of treat-to-target combination therapy with intensification at 13 weeks in early RA.
The association between autoantibodies and risk for venous thromboembolic events among patients with rheumatoid arthritis
Helga Westerlind, Alf Kastbom, Johan Rönnelid, Monika Hansson, Lars Alfredsson, Linda Mathsson-Alm, Guy Serre, Martin Cornillet, Rikard Holmdahl, Karl Skriner, Holger Bang, Lars Klareskog, Saedis Saevarsdottir, Karin Lundberg, Caroline Grönwall, Johan Askling
doi : 10.1093/rheumatology/keac601
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2106–2112
To assess the association between venous thromboembolic (VTE) events and autoantibodies, following patients from RA diagnosis, measuring occurrence, levels and collective load of different autoantibodies against post-translational protein modifications, in particular recognizing citrullination (e.g. citrullinated fibrinogen) and RF by isotype.
Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study
Lars Erik Kristensen, Mauro Keiserman, Kim Papp, Leslie McCasland, Douglas White, Wenjing Lu, Ahmed M Soliman, Ann Eldred, Lisa Barcomb, Frank Behrens
doi : 10.1093/rheumatology/keac607
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2113–2121
PsA is a chronic disease with heterogeneous clinical manifestations requiring treatment options with long-term efficacy and safety. In this follow-up analysis, the 52-week efficacy and safety of risankizumab 150 mg in patients with active PsA who had previous inadequate response/intolerance to one or more conventional synthetic DMARDs (csDMARD-IR) were evaluated.
Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study
Andrew Östör, Filip Van den Bosch, Kim Papp, Cecilia Asnal, Ricardo Blanco, Jacob Aelion, Wenjing Lu, Zailong Wang, Ahmed M Soliman, Ann Eldred, Byron Padilla, Alan Kivitz
doi : 10.1093/rheumatology/keac605
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2122–2129
PsA is a chronic inflammatory disease in which the skin and joints are affected. In this follow-up analysis, the 52-week efficacy and safety of risankizumab 150 mg in patients with active PsA who had previous inadequate response/intolerance to one or two biologic therapies (Bio-IR) or one or more conventional synthetic DMARDs (csDMARD-IR) were evaluated.
Performance of an MRI scoring system for inflammation of joints and entheses in peripheral SpA: post-hoc analysis of the CRESPA trial
Simon Krabbe, Thomas Renson, Lennart Jans, Dirk Elewaut, Filip Van den Bosch, Philippe Carron, Mikkel Østergaard
doi : 10.1093/rheumatology/keac567
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2130–2138
The aim of this study was to investigate the reliability, validity, and sensitivity to change of a novel MRI scoring system in early peripheral SpA (pSpA).
The effect of anti-inflammatory treatment on depressive symptoms in spondyloarthritis: does the type of drug matter?
Casper Webers, Uta Kiltz, Jürgen Braun, Désirée van der Heijde, Annelies Boonen
doi : 10.1093/rheumatology/keac580
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2139–2146
To investigate the effect of pharmacological treatment of SpA on depressive symptoms and explore whether this effect differs between drug classes.
Trust in the attending rheumatologist, health-related hope and medication adherence among Japanese systemic lupus erythematosus patients
Noriaki Kurita, Nao Oguro, Yoshia Miyawaki, Chiharu Hidekawa, Natsuki Sakurai, Takanori Ichikawa, Yuichi Ishikawa, Keigo Hayashi, Kenta Shidahara, Dai Kishida, Ryusuke Yoshimi, Ken-ei Sada, Yasuhiro Shimojima, Nobuyuki Yajima
doi : 10.1093/rheumatology/keac565
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2147–2153
Poor medication adherence among patients with SLE is a critical problem associated with adverse outcomes. This study examined the relationship between trust in one’s physician and goal-oriented thinking, hope and medication adherence among Japanese patients with SLE who were ethnically matched to their physicians.
Grit personality of physicians and achievement of treatment goals in patients with system lupus erythematosus
Ken-ei Sada, Yoshia Miyawaki, Kenta Shidahara, Shoichi Nawachi, Yu Katayama, Yosuke Asano, Keigo Hayashi, Keiji Ohashi, Eri Katsuyama, Takayuki Katsuyama, Mariko Takano-Narazaki, Yoshinori Matsumoto, Nao Oguro, Yuichi Ishikawa, Natsuki Sakurai, Chiharu Hidekawa, Ryusuke Yoshimi, Dai Kishida, Takanori Ichikawa, Yasuhiro Shimojima, Noriaki Kurita, Nobuyuki Yajima
doi : 10.1093/rheumatology/keac612
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2154–2159
Although personality characteristics of patients with SLE affect their disease activity and damage, it is unclear whether those of attending physicians affect the outcomes of patients with SLE. Grit is a personality trait for achieving long-term goals that may influence the decision-making for continuing treatment plans for patients. We aimed to evaluate the relationship between the grit of attending physicians and achievement of treatment goals in patients with SLE.
‘I turned in my man card’: a qualitative study of the experiences, coping styles and support needs of men with systemic sclerosis
Caroline A Flurey, John D Pauling, Lesley Ann Saketkoo, Christopher P Denton, Paul Galdas, Dinesh Khanna, Adrian Williams, Michael Hughes
doi : 10.1093/rheumatology/keac585
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2160–2167
Men with SSc have a more severe clinical phenotype and reduced survival compared with women. No previous psychosocial studies have focused solely on men with SSc. This study aimed to explore experiences, coping strategies and support preferences of men with SSc.
Functional autoantibodies in systemic sclerosis: influence of autologous stem cell transplantation and correlation with clinical outcome
Lukas Bankamp, Beate Preuß, Ann-Christin Pecher, Wichard Vogel, Jörg Henes, Reinhild Klein
doi : 10.1093/rheumatology/keac549
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2168–2177
To evaluate the effect of autologous stem cell transplantation (aSCT) on functional antibodies (abs) to the angiotensin II type-1-receptor (AT1R) and topoisomerase-I (topo-I) in SSc-patients and to analyse their prognostic relevance.
Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region
Alain Lescoat, Dörte Huscher, Nils Schoof, Paolo Airò, Jeska de Vries-Bouwstra, Gabriela Riemekasten, Eric Hachulla, Andrea Doria, Edoardo Rosato, Nicolas Hunzelmann, Carlomaurizio Montecucco, Armando Gabrielli, Anna-Maria Hoffmann-Vold, Oliver Distler, Jennifer Ben Shimol, Maurizio Cutolo, Yannick Allanore, the EUSTAR collaborators
doi : 10.1093/rheumatology/keac576
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2178–2188
The prevalence and characteristics of SSc-associated interstitial lung disease (SSc-ILD) vary between geographical regions worldwide. The objectives of this study were to explore the differences in terms of prevalence, phenotype, treatment and prognosis in patients with SSc-ILD from predetermined geographical regions in the EUSTAR database.
Cutaneous vasculitis occurring in the setting of systemic lupus erythematosus: a multicentre cohort study
Paul Breillat, Marie Jachiet, Yoan Ditchi, Cédric Lenormand, Nathalie Costedoat-Chalumeau, Alexis Mathian, Philippe Moguelet, Paul Duriez, Marten Trendelenburg, Uyen Huynh-Do, Carlo Chizzolini, Clément Beuvon, Frederique Roy-Peaud, Jean-David Bouaziz, Annick Barbaud, Camille Francès, Arsène Mékinian, Olivier Fain, Zahir Amoura, François Chasset, for EMSED study group (Etude des maladies systémiques en dermatologie) and the Swiss SLE Cohort Study (SSCS)
doi : 10.1093/rheumatology/keac566
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2189–2196
To describe the clinical and pathological features of biopsy-proven cutaneous vasculitis (CV) associated with SLE, focusing on diagnosis classification and impact on overall SLE activity.
Added diagnostic yield of temporal artery magnetic resonance angiography in the evaluation of giant cell arteritis
Mats L Junek, Shaista Riaz, Stephanie Garner, Nader Khalidi, Ryan Rebello
doi : 10.1093/rheumatology/keac583
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2197–2202
Temporal artery magnetic resonance angiography (TAMRA) is a useful tool to investigate possible diagnoses of GCA. As acquired images also reveal other local structures, they may assist in finding alternative diagnoses when assessing for possible GCA. We sought to assess the utility of TAMRA in identifying other significant abnormalities either associated with a diagnosis of GCA or potentially mimicking a clinical presentation of GCA.
Angiotensin receptor blockade is associated with increased risk of giant cell arteritis
Sizheng Steven Zhao, Houchen Lyu, Chao Zeng, Guanghua Lei, Jie Wei, Sarah L Mackie
doi : 10.1093/rheumatology/keac599
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2203–2210
Angiotensin II is implicated in GCA pathology. We examined whether the use of angiotensin receptor blockers (ARBs) is associated with GCA risk compared with angiotensin-converting enzyme inhibitors (ACEis) or other antihypertensives.
The adjusted Global Anti-Phospholipid Syndrome Score as predictor of damage accrual measured by Damage Index for APS: a longitudinal study
Giuseppe Barilaro, Carlo Della Rocca, Alexandra Esteves, Ricard Cervera, Gerard Espinosa
doi : 10.1093/rheumatology/keac619
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2211–2219
To analyse the association between the average ‘adjusted’ Global APS Score (aGAPSS) over time, as a surrogate of disease activity, and change in Damage Index for APS (DIAPS) during follow-up in patients with thrombotic and non-thrombotic APS.
Revisiting idiopathic eosinophilic myositis: towards a clinical-pathological continuum from the muscle to the fascia and skin
Cécile Fermon, Lola E R Lessard, Tanguy Fenouil, Alain Meyer, Marie Faruch-Bilfeld, Marie Robert, Verena Landel, Arnaud Hot, François-Jérôme Authier, Nathalie Streichenberger, Laure Gallay
doi : 10.1093/rheumatology/keac556
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2220–2229
Biologics with or without methotrexate in treatment of polyarticular juvenile idiopathic arthritis: effectiveness, safety and drug survival
Franz Thiele, Ariane Klein, Jens Klotsche, Daniel Windschall, Frank Dressler, Jasmin Kuemmerle-Deschner, Kirsten Minden, Ivan Foeldvari, Dirk Foell, Sonja Mrusek, Prasad Thomas Oommen, Gerd Horneff
doi : 10.1093/rheumatology/keac587
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2230–2238
To investigate the impact of additionally given MTX on biologic treatment of polyarticular JIA in terms of effectiveness, safety and drug survival.
Comprehensive and reliable sonographic assessment and scoring system for inflammatory lesions of the paediatric ankle
Patricia Vega-Fernandez, Deirdre De Ranieri, Edward Oberle, Matthew Clark, Hulya Bukulmez, Clara Lin, Susan Shenoi, Akaluck Thatayatikom, Leandra Woolnough, Heather Benham, Emily Brunner, Michael Henrickson, Laura R Pratt, Jean-Philippe Proulx-Gauthier, Ginger Janow, Amy Cassedy, Tracy V Ting, Johannes Roth for
doi : 10.1093/rheumatology/keac622
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2239–2246
The clinical decision-making process in paediatric arthritis lacks an objective, reliable bedside imaging tool. The aim of this study was to develop a US scanning protocol and assess the reliability of B-mode and Doppler scoring systems for inflammatory lesions of the paediatric ankle.
Nationwide racial/ethnic disparities in US emergency department visits and hospitalizations for gout
Chio Yokose, Natalie McCormick, Na Lu, Amit D Joshi, Lesley Jackson, Minna J Kohler, Janeth Yinh, Yuqing Zhang, John Hsu, Nicola Dalbeth, Kenneth G Saag, Hyon K Choi
doi : 10.1093/rheumatology/keac590
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2247–2251
Gout prevalence is reportedly ∼20% higher in US Black adults than Whites, but racial differences in emergency department (ED) visits and hospitalizations for gout are unknown. We evaluated the latest US national utilization datasets according to racial/ethnic groups.
Antiphospholipid antibody positivity in early systemic lupus erythematosus is associated with subsequent vascular events
Nicola Farina, Ruya Abdulsalam, Thomas McDonnell, Charis Pericleous, Amrita D’Souza, Vera M Ripoll, Jemma Webster, David A Isenberg, Ian Giles, Anisur Rahman
doi : 10.1093/rheumatology/keac596
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2252–2256
aPL are found in the blood of 20–30% of patients with SLE. Although aPL cause vascular thrombosis in the antiphospholipid syndrome, it is not clear whether positive aPL levels in early SLE increase risk of subsequent vascular events (VE).
External validation of the alternative Ankylosing Spondylitis Disease Activity Score in three randomized clinical trials of ixekizumab
Augusta Ortolan, Sofia Ramiro, Roberta Ramonda, Désirée van der Heijde
doi : 10.1093/rheumatology/keac618
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2257–2261
The alternative ASDAS (altASDAS) is an index that can be used when patient global assessment is unavailable. Our aim was to test the truth and discrimination aspects according to OMERACT filter 2.0 of the altASDAS in an external cohort.
Inactivated SARS-CoV-2 vaccine does not increase the risk of relapse in patients with clinically inactive adult-onset Still’s disease
Xinyue Hong, Haoyu Pan, Yutong Su, Qiongyi Hu, Yue Sun, Honglei Liu, Xiaobing Cheng, Junna Ye, Hui Shi, Jianfen Meng, Zhuochao Zhou, Jinchao Jia, Tingting Liu, Mengyan Wang, Xia Chen, Yuning Ma, Zihan Tang, Fan Wang, Hao Zhang, Yijun You, Dehao Zhu, Longfang Chen, Chengde Yang, Jialin Teng, Huihui Chi
doi : 10.1093/rheumatology/keac620
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2262–2266
A succession of cases have reported flares of adult-onset Still’s disease (AOSD) after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), raising concerns. We aimed to investigate the impact of inactivated SARS-CoV-2 vaccines on disease activity in patients with AOSD.
Relevance of leukaemia inhibitory factor to anti-melanoma differentiation-associated gene 5 antibody-positive interstitial lung disease
Yuki Ichimura, Hiroyuki Ikei, Risa Konishi, Moko Zeniya, Takahiro Okai, Toshifumi Nomura, Kousuke Negishi, Naoko Okiyama
doi : 10.1093/rheumatology/keac632
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2267–2271
Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive rapidly progressive interstitial lung disease (RP-ILD) is a life-threatening disease, the aetiology of which remains unclear. To detect potential diagnostic markers, a transcriptome analysis of the lung sample from a patient with anti-MDA5 antibody-positive RP-ILD was performed.
Development of a scoring model for the Sharp/van der Heijde score using convolutional neural networks and its clinical application
Suguru Honda, Koichiro Yano, Eiichi Tanaka, Katsunori Ikari, Masayoshi Harigai
doi : 10.1093/rheumatology/keac586
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2272–2283
To construct a predictive model for the Sharp/van der Heijde score (SHS) and assess its applicability in clinical research settings.
Autoimmune activation and hypersensitization of the AT1 and ETA receptors contributes to vascular injury in scleroderma renal crisis
Björn Hegner, Tobias Kretzschmar, Nan Zhu, Gunnar Kleinau, Hongfan Zhao, Julian Kamhieh-Milz, Julia Hilger, Ralf Schindler, Patrick Scheerer, Gabriela Riemekasten, Aurélie Philippe, Rusan Catar
doi : 10.1093/rheumatology/keac594
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2284–2293
Scleroderma renal crisis (SRC) is a rare vascular complication of systemic sclerosis with substantial risks for end-stage renal disease and premature death. Activating autoantibodies (Abs) targeting the angiotensin II type 1 (AT1R) and the endothelin-1 type A receptor (ETAR) have been identified as predictors for SRC.
Humoral and cellular immunity in patients with rare autoimmune rheumatic diseases following SARS-CoV-2 vaccination
Leher Gumber, Nancy Gomez, Georgina Hopkins, Davis Tucis, Laura Bartlett, Kieran Ayling, Kavita Vedhara, Graham Steers, Mithun Chakravorty, Megan Rutter, Hannah Jackson, Patrick Tighe, Alastair Ferraro, Sheila Power, Marie-Josèphe Pradère, David Onion, Peter C Lanyon, Fiona A Pearce, Lucy Fairclough
doi : 10.1093/rheumatology/keac574
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2294–2303
Coronavirus 2019 vaccine responses in rare autoimmune rheumatic diseases (RAIRDs) remain poorly understood; in particular there is little known about whether people develop effective T cell responses.
Analyses of plasma inflammatory proteins reveal biomarkers predictive of subsequent development of giant cell arteritis: a prospective study
Karin Wadström, Lennart T H Jacobsson, Aladdin J Mohammad, Kenneth J Warrington, Eric L Matteson, Magnus E Jakobsson, Carl Turesson
doi : 10.1093/rheumatology/keac581
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2304–2311
To investigate the relation between biomarkers of inflammation and subsequent development of GCA.
Citrullinated and carbamylated proteins in extracellular microvesicles from plasma of patients with rheumatoid arthritis
Federica M Ucci, Serena Recalchi, Cristiana Barbati, Valeria Manganelli, Antonella Capozzi, Gloria Riitano, Giorgia Buoncuore, Tina Garofalo, Fulvia Ceccarelli, Francesca R Spinelli, Eugenia Balbinot, Alessandra Ida Celia, Agostina Longo, Cristiano Alessandri, Roberta Misasi, Maurizio Sorice, Fabrizio Conti
doi : 10.1093/rheumatology/keac598
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2312–2319
To investigate the expression of citrullinated and carbamylated proteins in extracellular microvesicles (EMVs) from RA patients.
WDFY4 polymorphisms in Chinese patients with anti-MDA5 dermatomyositis is associated with rapid progressive interstitial lung disease
Li Guo, Xueliang Zhang, Weilin Pu, Jiangfeng Zhao, Kaiwen Wang, Danting Zhang, Soonmin Hong, Yanyun Ma, Xiaodong Wang, Shuang Ye, Qiang Guo, Jiucun Wang
doi : 10.1093/rheumatology/kead006
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2320–2324
Anti-melanoma differentiation-associated gene 5 antibody positive dermatomyositis (MDA5+DM), is susceptible to development of rapidly progressive interstitial lung disease (RPILD), which has been predominantly reported in East Asia.
A deep learning system for quantitative assessment of microvascular abnormalities in nailfold capillary images
Praveen Gurunath Bharathi, Michael Berks, Graham Dinsdale, Andrea Murray, Joanne Manning, Sarah Wilkinson, Maurizio Cutolo, Vanessa Smith, Ariane L Herrick, Chris J Taylor
doi : 10.1093/rheumatology/kead026
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2325–2329
Nailfold capillaroscopy is key to timely diagnosis of SSc, but is often not used in rheumatology clinics because the images are difficult to interpret. We aimed to develop and validate a fully automated image analysis system to fill this gap.
Correction to: Continuing specialist care into adulthood in young people with juvenile idiopathic arthritis: a retrospective cohort study using electronic health records in England
doi : 10.1093/rheumatology/kead005
Rheumatology, Volume 62, Issue 6, June 2023, Page 2330
Correction to: Clinical and biomechanical factors associated with falls and rheumatoid arthritis: baseline cohort with longitudinal nested case–control study
doi : 10.1093/rheumatology/kead043
Rheumatology, Volume 62, Issue 6, June 2023, Page 2331
COVID-19 vaccine safety during the antenatal period in women with idiopathic inflammatory myopathies
Laura Andreoli, Parikshit Sen, Daniele Lini, Melinda Nagy Vincze, Karen Schreiber, Vikas Agarwal, Rohit Aggarwal, Latika Gupta, COVAD Study Group
doi : 10.1093/rheumatology/keac644
Rheumatology, Volume 62, Issue 6, June 2023, Pages e175–e179
Utilization of electronic health record data to evaluate the association of urban environment with systemic lupus erythematosus symptoms
Janet Song, Noah Forrest, Adam Gordon, Leah Kottyan, Kathleen F Mittendorf, Wei-Qi Wei, Rosalind Ramsey-Goldman, Theresa Walunas, Abel Kho
doi : 10.1093/rheumatology/keac647
Rheumatology, Volume 62, Issue 6, June 2023, Pages e180–e181
Association between disability scores and opioid use in patients with psoriatic arthritis and ankylosing spondylitis
Alexis Ogdie, Mark Hwang, Sofia Pedro, Phani Veeranki, Esther Yi, Steven Hass, Kaleb Michaud
doi : 10.1093/rheumatology/keac673
Rheumatology, Volume 62, Issue 6, June 2023, Pages e182–e184
COVID-19 antiviral therapy for non-hospitalized immunosuppressed patients with rheumatic diseases is feasible with positive outcomes
Chung M A Lin, Josh Bennett, Lavanya Rajagopala, Ewan Hunter, Alice R Lorenzi, Bridget Griffiths, Kenneth F Baker
doi : 10.1093/rheumatology/keac705
Rheumatology, Volume 62, Issue 6, June 2023, Pages e185–e187
Brain oedema due to disseminated intravascular coagulation in a patient with adult-onset Still’s disease–associated hemophagocytic lymphohistiocytosis—a case report
Georg Lorenz, Christian Schaaf, Philipp Moog, Quirin Bachmann, Florian Popp, Jürgen Rech, Johanna Schorr, Carmen Gabl, Claudius Küchle, Claire Delbridge, Gregor G Weirich, Uwe Heemann, Gerhard Schneider, Nicole Lange, Matias Wagner, Wiebke Berg-Johnson
doi : 10.1093/rheumatology/keac595
Rheumatology, Volume 62, Issue 6, June 2023, Pages e188–e190
Immune checkpoint inhibitor-induced radiation recall myositis
Hirotaka Yamamoto, Yoshinori Taniguchi
doi : 10.1093/rheumatology/keac636
Rheumatology, Volume 62, Issue 6, June 2023, Pages e191–e192
A case of A20 haploinsufficiency in which intestinal inflammation improved with thalidomide
Kanako Mitsunaga, Yuzaburo Inoue, Chie Naito, Hitoshi Ogata, Yoshinobu Itoh, Yoshiko Natsui, Takeshi Saito, Minako Tomiita
doi : 10.1093/rheumatology/keac634
Rheumatology, Volume 62, Issue 6, June 2023, Pages e193–e195
A novel frameshift variant in TNFRSF13B in a Chinese patient with late-onset combined immunodeficiency
Junke Miao, Min Shen
doi : 10.1093/rheumatology/keac681
Rheumatology, Volume 62, Issue 6, June 2023, Pages e196–e198
Comment on: Text neck misdiagnosed as fibromyalgia
Ney Meziat-Filho, Tatiana Grasser, Igor Correia, Felipe J J Reis
doi : 10.1093/rheumatology/keac642
Rheumatology, Volume 62, Issue 6, June 2023, Pages e199–e200
Comment on: Text neck misdiagnosed as fibromyalgia. Reply
Taro Horino, Hiroshi Ohnishi, Masahiro Komori, Yoshio Terada
doi : 10.1093/rheumatology/keac643
Rheumatology, Volume 62, Issue 6, June 2023, Page e201
Comment on: The association between autoantibodies and risk for venous thromboembolic events among patients with rheumatoid arthritis
Duygu Tecer, Muhammet Cinar, Sedat Yilmaz
doi : 10.1093/rheumatology/keac648
Rheumatology, Volume 62, Issue 6, June 2023, Pages e202–e203
Comment on: The association between autoantibodies and risk for venous thromboembolic events among patients with rheumatoid arthritis: reply
Helga Westerlind, Alf Kastbom, Johan Askling
doi : 10.1093/rheumatology/keac649
Rheumatology, Volume 62, Issue 6, June 2023, Page e204
Multicentric Castleman disease with trismus
Takuya Kakutani, Masaki Yoshizawa
doi : 10.1093/rheumatology/keac611
Rheumatology, Volume 62, Issue 6, June 2023, Pages e205–e206
Bilateral sclerochoroidal calcification in a patient with calcium pyrophosphate deposition disease
Tuba Demirci Yildirim, Turhan Mammadov, Ali Osman Saatci, Ismail Sari
doi : 10.1093/rheumatology/keac633
Rheumatology, Volume 62, Issue 6, June 2023, Pages e207–e208
Ixekizumab-associated disseminated tinea corporis in a patient with psoriatic arthritis and plaque psoriasis
Kamran Naraghi, Kave Shams, Helena Marzo-Ortega
doi : 10.1093/rheumatology/keac635
Rheumatology, Volume 62, Issue 6, June 2023, Pages e209–e210
